Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy

3 lutego 2015 zaktualizowane przez: Frank Lippert
The study will be randomized, investigator-blind, observer-blind, laboratory analyst-blind and will utilize a 5-way cross-over study design with a primary objective to determine if a higher dose of fluoride in milk will provide a greater caries preventive effect. Secondary objectives are to determine in a higher concentration of fluoride in milk will provide a greater caries preventive effect and if the caries preventive effect of fluoridated milk follows a dose-response pattern.

Przegląd badań

Szczegółowy opis

The evidence of milk fluoridation as a public health measure in caries prevention has been demonstrated in many clinical studies. While these data are encouraging, the main focus now should be on the optimization of milk fluoride programs. This protocol will concentrate on the parameters of fluoride dose and concentration utilizing an in situ model, the intra-oral caries test or model (ICT). The ICT is an established model which features the use of gauze-covered specimens to facilitate plaque growth and to simulate a caries-prone/plaque stagnation area. After subject has been consented and enrolled in the study per the inclusion/exclusion criteria, two to three days following a dental cleaning, two partially demineralized specimens will be placed in the buccal flange area of the subject's mandibular partial denture. During each of the five, three-week test periods, subjects will drink their assigned milk test product once per day for either five (100 ml milk) or ten (200 ml milk) timed minutes, wearing their mandibular partial dentures 24 hours a day during the test period. Fluoride free toothpaste will be used two to three days before and continuously during each treatment period. After each three-week test period, the two partially demineralized specimens will be removed from the subject's partial denture and analyzed using the surface microhardness test. Mineral content change (as percentage of surface microhardness recovery) in these artificially induced incipient enamel lesions will be the primary outcome variable. Each subject (n = 28) will serve as his or her own control.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

28

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Indiana
      • Indianapolis, Indiana, Stany Zjednoczone, 46202
        • Oral Health Research Institute, Indiana University School of Dentistry

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 80 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • sign an informed consent, authorization for the release of health information for research and provide medical history information, including medications, prior to their participation;
  • be between 18 and 80 years old and in general good health;
  • willingness to use a reliable form of contraception or abstaining during the course of the study (females of child-bearing potential only)
  • wear a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two enamel specimens (required dimensions 12×7 mm);
  • be willing and capable of wearing their removable mandibular partial dentures 24 hours a day for a total of five, three-week test periods;
  • be in good dental health with no active caries or periodontal disease;
  • agree to comply with all subjects' responsibilities as stated in the protocol (e.g. use of study products, attendance at appointments, etc.);
  • have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 ml/min; gum base stimulated whole saliva flow rate ≥ 0.8 ml/min).
  • Be able to tolerate the taste and room temperature of the mixed milk product as demonstrated by drinking the milk at screening

Exclusion Criteria:

be pregnant, intending to become pregnant during the study period or breast feeding. A urine pregnancy test will be required at screening, the start of each treatment visit and the last study visit for all subjects of child-bearing potential to confirm the subject is not pregnant.

  • have any medical condition that could be expected to interfere with the subject's safety during the study period;
  • demonstrate an inability to comply with study procedures;
  • have factors which could contraindicate their participation, such as any condition requiring the need for antibiotic premedication prior to a dental treatment, a condition requiring the need for long-term antibiotic use, blood thinning medications that prohibit the safe conduct of a dental cleaning* or previous use of the weight loss medications Fen Phen® or Redux®. (*Note: Subjects who are taking blood thinners in which written verification is obtained from their physician indicating their PT/INR levels (anti-coagulation blood levels) are at an acceptable level to avoid serious complications, such as bleeding during dental cleanings, may be accepted into the study at the discretion of the Investigator.)
  • be currently taking or have ever taken a bisphosphonate drug (i.e. Fosamax®, Actonel®, Boniva®, Reclast®, or Zometa®) for treatment of osteoporosis.
  • be lactose intolerant or have known allergy or intolerance to milk or milk products

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie krzyżowe
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Inny: Arm 1
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • Kroger Nonfat Dry Milk
Inny: Arm 2
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • Kroger Nonfat Dry Milk
Inny: Arm 3
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • Kroger Nonfat Dry Milk
Inny: Arm 4
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • Kroger Nonfat Dry Milk
Aktywny komparator: Arm 5
non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design
Inne nazwy:
  • sodium fluoride (PCCA Sodium Fluoride USP 51927-1038-00)
  • Kroger Nonfat Dry Milk reconstituted with fluoride-free milk
Each subject will use this product during one of the five treatment periods in the crossover study design.
Inne nazwy:
  • Kroger Nonfat Dry Milk

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
% Surface Microhardness (SMH) Recovery Score Per Each of Five Arms
Ramy czasowe: Three Weeks per each of five arms
  • surface microhardness recovery is a measure of caries lesion remineralization and is calculated using the following equation:
  • SMHr=(D1-R)/(D1-B)×100 B = indentation length of sound enamel specimen at baseline D1 = indentation length after first in vitro demineralization R = indentation length after intra-oral exposure (rehardening).
Three Weeks per each of five arms

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
% Acid Resistance Score Per Each of Five Arms
Ramy czasowe: Three Weeks per each of five arms
% Acid Resistance is a measure of acid resistance of the remineralized caries lesion which is calculated as (D1-D2)/(D1-B)*100%, where B is the indentation length of sound enamel specimen at baseline, D1 is an indentation length after first in vitro demineralization, D2 is an indentation length after second in vitro demineralization.
Three Weeks per each of five arms
Enamel Fluoride Uptake Per Each of Five Arms
Ramy czasowe: Three Weeks per each of five arms
Enamel fluoride uptake is a measure of fluoridation of a caries lesion
Three Weeks per each of five arms

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Główny śledczy: Domenick Zero, DDS, MS, Indiana University

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 sierpnia 2012

Zakończenie podstawowe (Rzeczywisty)

1 kwietnia 2013

Ukończenie studiów (Rzeczywisty)

1 czerwca 2013

Daty rejestracji na studia

Pierwszy przesłany

7 sierpnia 2012

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 sierpnia 2012

Pierwszy wysłany (Oszacować)

16 sierpnia 2012

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

23 lutego 2015

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

3 lutego 2015

Ostatnia weryfikacja

1 lutego 2015

Więcej informacji

Terminy związane z tym badaniem

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj